Iceland· IS-EU/1/17/1218/001-002
Rydapt
A midostaurin product containing midostaurinum inn, registered in Iceland by Novartis Europharm Limited*. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Midostaurin is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EX10 (midostaurin), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Midostaurin · ATC L01EX10
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Midostaurinum INN
- Manufacturer
- Novartis Europharm Limited*
- Country
- Iceland (IS)
- ATC code
- L01EX10
- ATC class
- Midostaurin
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 2
2 priced- ean500476112 stk x1 þpakkiISK 2289786
- ean51975556 stk x1 þpakkiISK 1111261
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
582 interactions on record for midostaurin.
Graded by severity as the source publishes them — 132 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Midostaurin · interactions on record
582 records
- 132 severe
- 445 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Midostaurin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandRydaptNovartis Europharm Limited
- CzechiaRYDAPTNovartis Europharm Limited, Dublin
- SwitzerlandRydapt 25 mg, WeichkapselnNovartis Pharma Schweiz AG
- United StatesRYDAPTNovartis Pharmaceuticals Corporation
- NorwayRydaptNovartis Europharm Limited (1)
- PolandRydaptNovartis Europharm Limited
- SwedenRydapt 25 mg Kapsel, mjukNovartis Europharm Limited
- FranceRYDAPT 25 mg, capsule molleNOVARTIS EUROPHARM (IRLANDE)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Rydapt
- Norway · Rydapt
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/efac7f5f-3295-4406-bd6a-a3611dc57548 GET /v1/drugs/efac7f5f-3295-4406-bd6a-a3611dc57548?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Mjúkt hylki",
"source": "lyfjastofnun",
"atc_raw": "L01EX10",
"marketed": true,
"strength": "25 mg",
"ma_number": "EU/1/17/1218/001-002",
"substance": "Midostaurinum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum og krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42996"
}See everything about midostaurin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.